Agenus (NASDAQ:AGEN) Stock Rating Lowered by Robert W. Baird

Robert W. Baird downgraded shares of Agenus (NASDAQ:AGEN) from an outperform rating to a neutral rating in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The firm currently has $8.00 price target on the biotechnology company’s stock, down from their prior price target of $35.00.

A number of other brokerages have also recently commented on AGEN. William Blair cut Agenus from an outperform rating to a market perform rating in a research note on Thursday. HC Wainwright cut Agenus from a buy rating to a neutral rating and lowered their price target for the company from $40.00 to $9.00 in a research note on Thursday. Finally, StockNews.com began coverage on Agenus in a research note on Wednesday, April 17th. They issued a hold rating for the company. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, Agenus presently has a consensus rating of Hold and a consensus price target of $31.00.

Agenus Trading Down 17.9 %

Agenus stock opened at $5.99 on Friday. Agenus has a 1 year low of $4.78 and a 1 year high of $34.20. The company has a market cap of $125.79 million, a PE ratio of -0.47 and a beta of 1.32. The company’s 50-day moving average is $14.33 and its two-hundred day moving average is $12.82.

Agenus (NASDAQ:AGEN) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.58) by $0.54. The business had revenue of $28.01 million for the quarter, compared to analyst estimates of $40.70 million. Research analysts forecast that Agenus will post -9.7 EPS for the current year.

Institutional Trading of Agenus

A number of large investors have recently bought and sold shares of AGEN. Vanguard Group Inc. increased its stake in Agenus by 13.7% during the 1st quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after purchasing an additional 4,134,232 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Agenus by 3,008.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after acquiring an additional 2,232,064 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Agenus by 1,959.9% during the 1st quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after acquiring an additional 720,629 shares in the last quarter. Pennant Investors LP bought a new position in shares of Agenus during the 4th quarter worth approximately $389,000. Finally, Virtu Financial LLC bought a new position in shares of Agenus during the 4th quarter worth approximately $213,000. 61.46% of the stock is owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.